Ion Torrent Ships New RNA Sequencing Application as Fast, Easy, Affordable Alternative to Microarrays

CARLSBAD, California, May 28, 2011 -

- The Ion Total RNA-Seq Kit, created in partnership with Life
Technologies' Ambion(R) division, provides far more accurate and
comprehensive data

Life Technologies Corporation (www.lifetechnologies.com) (NASDAQ:
LIFE) today announced it is now shipping the Ion Total RNA-Seq Kit
(find.lifetechnologies.com/ionrnaseq/pr/ion-rnaseq-regional-86MH-784EI.html)
for the Ion Personal Genome Machine (PGM(TM)) sequencer, a solution
that provides a fast, affordable, easy-to-use alternative to microarrays for
transcript expression analysis. The Ion PGM sequencer puts RNA-Seq within the
reach of any lab, enabling scientists to get far more accurate and
comprehensive data than microarrays can provide for a comparable price.

RNA-Seq has always been the preferred method for studying gene expression
because it provides the most complete information, such as transcript
quantitation and the detection of novel transcripts and mutations. However,
the cost and complexity of high-throughput next-generation sequencing
(www.appliedbiosystems.com/absite/us/en/home/applications-technologies/semiconductor-sequencing.html)
technology has kept most researchers from adopting it.

"It's been clear for years that there's a huge disconnect between the
view of the transcriptome that we see from microarrays and the output of
individual biological states that we get with sequencing," said Dr. Sean
Grimmond, the Director of the Queensland Centre for Medical Genomics. "While
RNA-Seq offers fantastic sensitivity and discrimination, cost and speed have
been holding it back. Those are two areas where Ion Torrent technology
excels, so this will be a very compelling application."

The Ion RNA-Seq is making RNA sequencing accessible to every scientist in
world, with a fast, simple, solution that any lab can buy and use:

    - The workflow is fast: Single-day workflow and sequencing that
      takes about an hour, compared to several days on some next-gen
      sequencers.
    - The price is affordable: The Ion PGM sequencer costs just
      $49,500, less than a microarray scanner or any next-generation
      platform, and Ion chips start at $250. Ion RNA-Seq delivers a low
      per-sample price without having to pool hundreds of samples.
    - The workflow is easy: Any molecular biology lab can quickly
      master the workflow, and data analysis takes just 90 minutes with
      intuitive tools like Partek, which are familiar to microarray users.
    - The platform is scalable: Change the number of reads by just
      changing the chip.
    - The read lengths are long: At least 100 bp today, 200 bp by the
      end of 2011 and 400 bp in 2012, ideal for detecting splice junctions

The Ion Total RNA Kit can analyze any type of RNA, including
rRNA-depleted total RNA, poly(A) RNA, and small RNA. Unlike most other kits,
it preserves strand information by aligning all mapped reads in the direction
of transcription relative to the chromosomal strand, providing critical
information about the structure of the gene that improves accuracy.

The Ion Personal Genome Machine sequencer is for research use only. Not
for use in diagnostic procedures.

About Life Technologies Sequencing

Life Technologies is the world's leading provider of sequencing
technologies, offering the industry's gold standard capillary electrophoresis
technology with the Applied Biosystems(TM) 3500 Series Genetic Analyzers
(https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=catNavigate2&catID=606262),
next-generation sequencing technology with the Applied Biosystems(TM) 5500
Series SOLiD(TM) Sequencers
(www.appliedbiosystems.com/absite/us/en/home/applications-technologies/solid-next-generation-sequencing/next-generation-systems.html),
and semiconductor-based sequencing technology with the recently launched Ion
Personal Genome Machine (PGM(TM)) sequencer
(www.iontorrent.com/products-ion-pgm/).

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation (www.lifetechnologies.com) (NASDAQ:
LIFE) is a global biotechnology company dedicated to improving the human
condition. Our systems, consumables and services enable researchers to
accelerate scientific and medical advancements that make life even better.
Life Technologies customers do their work across the biological spectrum,
working to advance the fields of discovery and translational research,
molecular medicine, stem cell-based therapies, food safety and animal health,
and 21st century forensics. The company manufactures both molecular
diagnostic and research use only products. Life Technologies'
industry-leading brands are found in nearly every life sciences lab in the
world and include innovative instrument systems under the Applied Biosystems
and Ion Torrent names, as well as, the broadest range of reagents with its
Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan(R) products. Life
Technologies had sales of $3.6 billion in 2010, has a workforce of
approximately 11,000 people, has a presence in approximately 160 countries,
and possesses one of the largest intellectual property estates in the life
sciences industry, with approximately 3,900 patents and exclusive licenses.
For more information on how we are making a difference, please visit our
website: www.lifetechnologies.com.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about our
anticipated results that involve risks and uncertainties. Some of the
information contained in this press release, including, but not limited to,
statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause
actual results or events to differ materially from those expressed or implied
by such forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual
results to differ materially from those in the forward-looking statements are
detailed in filings made by Life Technologies with the Securities and
Exchange Commission. Life Technologies undertakes no obligation to update or
revise any such forward-looking statements to reflect subsequent events or
circumstances.

(Logo: photos.prnewswire.com/prnh/20110216/MM49339LOGO)

    Life Technologies Contact
    Wes Conard
    +1-650-243-6019
    Wesley.conard@lifetech.com

    Mauricio Minotta
    +1-760-929-2456
    Mauricio.minotta@lifetech.com

.